Company intelligence / Profile preview

Eyevance Pharmaceuticals

Fort Worth, Texas, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Eyevance has successfully commercialized several novel ophthalmic products, including ZERVIATE (the first topical cetirizine eye drop for allergic conjunctivitis), TOBRADEX ST, FLAREX, Natacyn, and Freshkote PF, addressing diverse ophthalmic conditions. Robust US sales infrastructure, ongoing product marketing, and high penetration in US ophthalmic market[2][4][5].

Therapeutic areas: ImmunologyInfectious DiseasesOphthalmology
Modalities: Small moleculeBiologicDevice
Industry: Biotech

Partnerships

Nicox (exclusive US license for ZERVIATE[2])Samil Pharmaceutical (ZERVIATE - South Korea, outside US)Ocumension Therapeutics (ZERVIATE – China, Southeast Asia, outside US)

Beyond the preview

Go deeper on Eyevance Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyevance Pharmaceuticals.

Explore the full profile